Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study.

Li X, Naylor MF, Le H, Nordquist RE, Teague TK, Howard CA, Murray C, Chen WR.

Cancer Biol Ther. 2010 Dec 1;10(11):1081-7. doi: 10.4161/cbt.10.11.13434. Epub 2010 Dec 1.

2.

In situ photoimmunotherapy: a tumour-directed treatment for melanoma.

Naylor MF, Chen WR, Teague TK, Perry LA, Nordquist RE.

Br J Dermatol. 2006 Dec;155(6):1287-92.

PMID:
17107404
3.

In situ photoimmunotherapy: a new hope for cutaneous melanoma patients.

Madhunapantula SV, Gowda R, Inamdar GS, Robertson GP.

Cancer Biol Ther. 2010 Dec 1;10(11):1088-90. Epub 2010 Dec 1. No abstract available.

PMID:
21178399
4.

In situ photoimmunotherapy: a surgery- and limb-sparing approach to the treatment of cutaneous metastases in advanced melanoma.

St Pierre SA, Rommel J, Ciurea A, Fife D, Yoo SS, Martini M, Kuzel TM, Wayne J, Rademaker A, West DP, Alam M.

Arch Dermatol. 2010 Aug;146(8):831-4. doi: 10.1001/archdermatol.2010.181. No abstract available.

PMID:
20713811
5.

In situ photoimmunotherapy for cutaneous granuloma caused by itraconazole-resistant Candida guilliermondii.

Shi L, Luo M, Chen WR, Hu C, Zhang G, Zhang F, Chen J, Mo X, Cai Q, Yang L, Wang X.

Dermatol Ther. 2016 Jun 21. doi: 10.1111/dth.12376. [Epub ahead of print]

PMID:
27328828
6.

Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.

Richtig E, Ludwig R, Kerl H, Smolle J.

Br J Dermatol. 2005 Nov;153(5):925-31.

PMID:
16225601
7.

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD.

Br J Dermatol. 2007 Feb;156(2):337-45.

PMID:
17223875
8.

Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.

Ridolfi L, Ridolfi R.

Hepatogastroenterology. 2002 Mar-Apr;49(44):335-9.

PMID:
11995445
9.

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.

Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B, Baudin M, Escudier B, Heinzerling L, Morant R, Herrmann R, Dietrich PY, Dummer R.

Cancer Gene Ther. 2002 Mar;9(3):289-95.

10.

Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.

Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R.

Clin Cancer Res. 2001 Aug;7(8):2285-91.

11.

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.

Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM.

Clin Cancer Res. 1998 Mar;4(3):619-27.

12.

Preliminary safety and efficacy results of laser immunotherapy for the treatment of metastatic breast cancer patients.

Li X, Ferrel GL, Guerra MC, Hode T, Lunn JA, Adalsteinsson O, Nordquist RE, Liu H, Chen WR.

Photochem Photobiol Sci. 2011 May;10(5):817-21. doi: 10.1039/c0pp00306a. Epub 2011 Mar 4.

PMID:
21373701
13.

Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.

Ridolfi L, Ridolfi R, Riccobon A, De Paola F, Petrini M, Stefanelli M, Flamini E, Ravaioli A, Verdecchia GM, Trevisan G, Amadori D.

J Immunother. 2003 Mar-Apr;26(2):156-62.

PMID:
12616107
14.

[Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].

Baldueva IA, Novik AV, Moiseenko VM, Nekhaeva TL, Danilova AB, Danilov AO, Protsenko SA, Petrova TIu, Uleń≠skaia GI, Shchekina LA, Semenova AI, Mikhań≠lichenko TD, Teletaeva GM, Zhabina AS, Volkov NV, Komarov IuI.

Vopr Onkol. 2012;58(2):212-21. Russian.

PMID:
22774527
15.

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R.

J Clin Oncol. 2006 Nov 1;24(31):5060-9.

17.

Prognostic factors in 1,521 melanoma patients with distant metastases.

Barth A, Wanek LA, Morton DL.

J Am Coll Surg. 1995 Sep;181(3):193-201.

PMID:
7670677
18.

Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide.

Elias EG, Suter CM, Fabian DS.

J Surg Oncol. 1997 Jan;64(1):17-22.

PMID:
9040795
19.

Ipilimumab in advanced melanoma: reports of long-lasting responses.

Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R.

Melanoma Res. 2012 Jun;22(3):263-70. doi: 10.1097/CMR.0b013e328353e65c.

PMID:
22516968
20.

Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine.

O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW.

Cancer Immunol Immunother. 2003 Jun;52(6):387-95. Epub 2003 Apr 8.

PMID:
12682787
Items per page

Supplemental Content

Write to the Help Desk